Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN By Ogkologos - January 9, 2026 437 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the GORTEC 2018-01 NIVOPOST-OP study Source RELATED ARTICLESMORE FROM AUTHOR Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength MOST POPULAR Identifying Safer Ways to Look for Recurrence After Testicular Cancer Surgery April 19, 2022 The Obesity Paradox: It Increases Diabetes Risk But Can Help Cancer... March 13, 2020 Discovering the BRCA2 gene – 25 years on January 14, 2021 Study Links Mental Health Treatment to Improved Cancer Survival July 10, 2020 Load more HOT NEWS Study Provides Closer Look at Postmenopausal Bleeding and Endometrial Cancer EMA Recommends Granting a Marketing Authorisation for a Biosimilar Bevacizumab, Onbevzi Remote Monitoring of Patients Treated with Oral Anticancer Drugs Improves Patient... Mom Diagnosed With Breast Cancer Adopts Healthy Lifestyle To Reinvent Her...
